Regeneron Files Q2 2024 10-Q
Ticker: REGN · Form: 10-Q · Filed: 2024-08-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Regeneron's Q2 2024 10-Q is in: financials and operations updated.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter of 2024. Key financial figures and business segments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and analysts with the latest financial health and operational performance of Regeneron, a major player in the biopharmaceutical industry.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate or unusual risk indicators.
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer
- 20240630 (date) — Period of Report
- 20240801 (date) — Filing Date
- TARRYTOWN (location) — Business Address City
- NY (location) — Business Address State
- 10591 (postal_code) — Business Address Zip
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the filing covers the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240801.
What is Regeneron Pharmaceuticals, Inc.'s primary industry classification?
Regeneron Pharmaceuticals, Inc. is classified under PHARMACEUTICAL PREPARATIONS [2834].
Where is Regeneron Pharmaceuticals, Inc. headquartered?
The company's business address is located at 777 Old Saw Mill River Road, Tarrytown, NY 10591.
What is the fiscal year end for Regeneron Pharmaceuticals, Inc.?
The company's fiscal year ends on 1231.
From the Filing
0001804220-24-000028.txt : 20240801 0001804220-24-000028.hdr.sgml : 20240801 20240801071521 ACCESSION NUMBER: 0001804220-24-000028 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 241164251 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-Q 1 regn-20240630.htm 10-Q regn-20240630 0000872589 12/31 2024 Q2 false xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure regn:claim 0000872589 2024-01-01 2024-06-30 0000872589 us-gaap:CommonClassAMember 2024-07-25 0000872589 us-gaap:CommonStockMember 2024-07-25 0000872589 2024-06-30 0000872589 2023-12-31 0000872589 us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonClassAMember 2024-06-30 0000872589 us-gaap:CommonStockMember 2024-06-30 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:ProductMember 2024-04-01 2024-06-30 0000872589 us-gaap:ProductMember 2023-04-01 2023-06-30 0000872589 us-gaap:ProductMember 2024-01-01 2024-06-30 0000872589 us-gaap:ProductMember 2023-01-01 2023-06-30 0000872589 regn:CollaborationRevenueMember 2024-04-01 2024-06-30 0000872589 regn:CollaborationRevenueMember 2023-04-01 2023-06-30 0000872589 regn:CollaborationRevenueMember 2024-01-01 2024-06-30 0000872589 regn:CollaborationRevenueMember 2023-01-01 2023-06-30 0000872589 us-gaap:ProductAndServiceOtherMember 2024-04-01 2024-06-30 0000872589 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0000872589 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-06-30 0000872589 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0000872589 2024-04-01 2024-06-30 0000872589 2023-04-01 2023-06-30 0000872589 2023-01-01 2023-06-30 0000872589 regn:CollaborationandContractManufacturingMember 2024-04-01 2024-06-30 0000872589 regn:CollaborationandContractManufacturingMember 2023-04-01 2023-06-30 0000872589 regn:CollaborationandContractManufacturingMember 2024-01-01 2024-06-30 0000872589 regn:CollaborationandContractManufacturingMember 2023-01-01 2023-06-30 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000872589 us-gaap:RetainedEarningsMember 2023-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000872589 2024-01-01 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-03-31 0000872589 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000872589 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0